Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer

This activity contains:

  • CME/CPE/CNE-Certified Web Archive

Release date: 5/3/2017
Expiration date: 5/2/2018
Estimated Time for Completion: 1 hour

Purpose
The goal of this activity is to provide physicians, nurses, pharmacists, and other healthcare professionals with an understanding of the latest clinical advances on the therapeutic options for the treatment of advanced HR-positive, HER2-negative breast cancer.

Activity Overview
Breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative represent the most common subtype of breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Endocrine therapy is currently the cornerstone of treatment for advanced HR-positive breast cancer. However, not all patients respond to first-line endocrine therapy, and those that do respond eventually experience disease relapse. Resistance to endocrine therapy is common, and complete disease resistance to additional endocrine therapy eventually develops in patients with HR-positive metastatic breast cancer (MBC). The 5-year and 10-year survival rates for MBC are 26% and 5% to 10%, respectively. Significant therapeutic advances in this area include the development of agents that target critical pathways involved in the development of resistance to endocrine therapy. These include mechanistic target of rapamycin (mTOR) inhibitors and cyclin-dependent kinase (CDK) 4/6 inhibitors.

This activity will review the mechanisms of action, efficacy, and safety of different classes of therapies, such as mTOR inhibitors and CDK 4/6 inhibitors, used in the treatment of advanced HR-positive, HER2-negative breast cancer so that clinicians can incorporate these therapies into their treatment plans for patients.

Target Audience

This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who manage breast cancer.

Course summary
Available credit: 
  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
05/03/2017
Course expires: 
05/02/2018
Cost:
$0.00
Rating: 
0

Chairperson

Harold J. Burstein, MD, PhD 
Associate Professor of Medicine
Medical Oncology, Solid Tumor Oncology
Harvard Medical School/Dana-Farber Cancer Institute
Boston, MA


Continuing Education

Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 


Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit. UAN 0592-0000-16-040-H01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or PresenterReported Financial Relationship
Harold J. Burstein, MD, PhDHarold J. Burstein, MD, PhD, has no real or apparent conflicts of interest to report.


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; Jocelyn Timko; and Marilyn Haas, PhD, RN, CNS, ANP-BC, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Stephanie Sutphin, PharmD, reports a financial interest/relationship or affiliation in the form of Advisory board: Seattle Genetics and Amgen Biosimilars.

This activity is supported by educational grants from Novartis Pharmaceuticals and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

There is no fee for this educational activity.

This activity is provided by:

AXIS 1475 WA

Available Credit

  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 AMA PRA Category 1 Credit™

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Differentiate the mechanisms of action of mTOR inhibitors and CDK 4/6 inhibitors
  • Summarize the efficacy and safety data for mTOR inhibitors and CDK 4/6 inhibitors in the setting of advanced HR-positive, HER2-negative breast cancer
  • Identify the clinical circumstances in which an mTOR inhibitor or a CDK 4/6 inhibitor would be an appropriate treatment option for a patient with breast cancer
  • Summarize strategies for effectively managing adverse events and facilitating patient adherence to therapy

Accreditation Period

Course opens: 
05/03/2017
Course expires: 
05/02/2018

Price

Cost:
$0.00
Please login or register to take this course.